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Learning points 
1. More than eleven million children are anti-HCV antibody positive worldwide and half of them 
are viremic needing treatment. 
 
2. Pegylated interferon in combination with ribavirin is the only currently approved therapy for 
children with HCV infection.  This therapeutic regime is suboptimally effective, requires 
subcutaneous injections, and is commonly associated with treatment-related adverse events. 
 
3. Newly developed direct acting antivirals (DAAs) are highly effective and safe drugs to treat 
HCV but are currently only approved for use in adults.  Preliminary data from ongoing pediatric 
trials show that DAAs are similarly effective and safe in children and adolescents. 
 
4. Cure of HCV infection is possible in almost all patients treated with interferon-free, oral DAA 
regimens.  HCV- infected children need to be targeted for DAA treatment as an integral 
component of the public health approach to the global eradication of HCV infection. 
 
5. Serious interplay between pediatric researchers, regulators and pharmaceutical industry 
leaders is essential to hasten the process of DAA approval for children with HCV infection. 
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Abstract 
The development of oral hepatitis C virus direct acting antivirals has revolutionized the 
therapeutic field. Nowadays, multiple safe and highly effective antiviral regimens are 
commercially available to treat adults with hepatitis C infection. These new regimens for the first 
time, genuinely raise the prospects of eradicating hepatitis C virus. However, many challenges 
remain: from identifying infected individuals to optimizing treatment and ensuring global access 
to antiviral therapy to all population groups, including children. The only drugs currently 
approved for children with chronic hepatitis C virus infection are pegylated interferon and 
ribavirin. There are four registered ongoing paediatric trials assessing safety and efficacy of 
direct acting antivirals but their current completion timelines are years away. Herein, we 
summarize the state of the art of direct acting antivirals development for adult and children and 
highlight the crucial importance of overcoming barriers to treating children with hepatitis C 
virus. 
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Introduction 
The discovery of hepatitis C virus (HCV) 25 years ago was a major scientific 
achievement when this elusive virus was isolated via a new expression-cloning technique (1). 
Subsequent molecular studies revealed HCV to be an RNA virus that replicates without a DNA 
intermediate (2). The characterization of HCV non-structural proteins (NS3-5), responsible for 
viral replication allowed for development of direct acting antiviral (DAA) targeting of NS3/4A 
protease, NS5A, and both nucleoside and non-nucleoside NS5B polymerase (3).  Since the 
introduction of the first generation DAAs (i.e., protease inhibitors) in 2011, HCV therapy has 
become one of the great success stories of basic, clinical and translational viral research.  Hence, 
our focus is to outline the development of DAAs; and, to review HCV oral, non-interferon 
therapy for adults, older adolescents and children.  Also, we will highlight pediatric barriers that 
must be overcome to allow children with chronic hepatitis to participate in this rapidly evolving 
post-interferon era which has revolutionized HCV therapy. 
Prevalence of Hepatitis C Virus 
 Chronic HCV is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC) 
worldwide.  Throughout this world, 130 million to 170 million people are chronically infected 
with HCV.  In the United States (US) prevalence is estimated to be 3.2 million individuals (4).  
Hepatitis C virus infection recently eclipsed human immunodeficiency virus infection as a cause 
of death in the US; the number of deaths because of HCV is not projected to peak until 2030 (5). 
Globally, 11 million of these infected individuals are <15 years of age; greater than 50% of all 
the children are from China, India, Russia, Nigeria, Pakistan, and Egypt (6).  Hepatitis C virus 
prevalence in the US and Europe ranges from 0.05 to 0.36%, and 1.8 to 5.8% in developing 
countries (7).  
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Direct-Acting Antiviral (DAA) Medications 
General Information.   The initial monotherapy trials of the first generation NS3/4A 
protease inhibitors were hindered by rapid selection of resistant variants (2).  It was also 
recognized that the standard of care with injected interferon-alpha combined with ribavirin 
showed activity against protease inhibitor-resistant HCV.  This antiviral therapy inhibits HCV 
replication, not by binding viral proteins, but by induction of antiviral and immunomodulatory 
effects.  Therefore, the key first step in the now recognized oral therapeutic revolution against 
HCV infection was the addition of a NS3/4a protease inhibitor to the standard treatment of 
peginterferon and ribavirin.  This strategy led to enhanced rates of HCV sustained virological 
rate (SVR) from approximately 45% to 75% among adult patients with genotype 1 HCV 
infection (2).  There was proof, therefore, that use of DAAs was clinically effective but the side-
effects of interferon-based regimens including cytopenias, autoimmune reactions and depression 
remained a limiting problem.  The subsequent rapid development of HCV NS5A inhibitors, and 
nucleoside/non-nucleoside NS5B polymerase inhibitors since 2011 is well reported, including 
new treatment combinations of HCV DAAs.  The most recent adult clinical trials have proved 
that interferon-free, all oral DAA combinations are consistently capable of producing SVR rates 
> 90 % (as defined by HCV RNA clearance 12-weeks after cessation of treatment; SVR12) (8-
10).  High optimism now exists for the global eradication of HCV infection (11). Table 1 
summarizes DAAs approved to date in adults.  First generation NS3/4 protease inhibitors such as 
telaprevir and boceprevir are no longer used because of their higher rates of adverse effects and 
treatment failures in real-world settings (11).   
Results of Clinical Trials in Adults and ‘Real-World’ experience.  In late 2013, 
sofosbuvir, a NS5B polymerase inhibitor (in combination with ribavirin), became the first 
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Federal Drug Administration (FDA)-approved DAA that allowed interferon-free therapy for 
HCV genotypes 2 and 3 (12).  Then, in early 2014, the ‘all oral’ DAA combination of sofosbuvir 
with a NS5A inhibitor, daclatasvir, was used for treatment-naïve adults with HCV genotypes 1, 
2, and 3 and HCV genotype 1 patients and previous protease inhibitor failure; SVR12 rates were 
excellent at > 93% (13). In a subsequent trial, previous non-responders infected with HCV 
genotype 1 treated with sofosbuvir and an NS3/4A protease inhibitor, simeprevir, with or 
without ribavirin achieved excellent SVR12 rates of 90% and 94%, respectively; in addition to a 
good safety profile and no apparent requirement for ribavirin (14).  Sofosbuvir and ledipasvir, 
another NS5A inhibitor, were co-formulated in 2016, as was the regimen of paritaprevir (NS3/4 
protease inhibitor boosted with ritonavir), ombitasvir (NS5A inhibitor) and dasabuvir (NS5B 
inhibitor).   
 Two phase-3 studies were reported in August 2016.  In OPTIMIST 1, sofosbuvir and 
simeprevir were combined to treat a large group of HCV-genotype 1 adults without cirrhosis 
who were treatment naïve and treatment experienced (15).  This regimen for 12-weeks was 
highly effective in the treatment of genotype 1a infected individuals without cirrhosis.  The 
overall SVR12 was 97%, superior to the historic rate of 87%.  In OPTIMIST 2 (16), the same 
12-week regimen in an open-label fashion was used, but the adult HCV genotype 1a patients had 
well-compensated cirrhosis.  In this difficult-to-treat group, the SVR12 was 83%, and emergent 
resistance-associated variants (RAVs) occurred based on treatment breakthroughs confirmed to 
be attributable to NS3/4a region mutation.  In a recent phase-3 DAA trial of untreated and 
treatment-experienced adults with HCV genotypes 1, 2, 4, 5 and 6, the use of fixed-dose 
combination sofosbuvir and velpatasvir (a novel NS5A inhibitor) led to an overall high rate of 
SVR12 of 99% (17).  Similarly, adults given this combination regimen with ‘difficult to treat’ 
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HCV genotypes 2 and 3, achieved SVR12 of 99% and 96%, respectively (18). Thus, these trials 
showed that treatment with sofosbuvir-velpatasvir were effective regardless of HCV genotype 
(pan-genotypic). Comprehensive, up-to-date HCV treatment recommendations sanctioned by the 
American Association for the Study of Liver Diseases, Infectious Disease Society of America, 
European and World Health Organization are available (8-10). 
The potential selection bias inherent to all registration studies raises questions about 
generalizing trial derived DAA efficacy and safety results to the adult HCV population at large. 
Thus, several HCV DAA ‘real-world’ registries including HCV-TARGET, ANRS CO22 
Hepather Cohort and the U.S. Veterans Study were developed. Initial results from these large 
adult cohorts that include patients with advanced liver disease, and those with contraindications 
to interferon and/or ribavirin and co-morbidities confirm that DAA therapy is highly effective 
and safe outside of the registration studies (19-21).   
Present Standard Treatment of HCV Infection in Children     
 The present standard of care for children and adolescents less than 18 years-old with 
chronic HCV infection is pegylated interferon with ribavirin (22-25).  This combination therapy 
results in a SVR of 52% of children with HCV genotype 1 and 4, after 48-weeks of therapy; and, 
89% for children with genotypes 2 and 3, after 24-weeks of treatment.  However, interferon 
regimens are of long duration, require injections to deliver medication, and drug effectiveness is 
limited by the side-effect profile that includes cytopenias, autoimmunity and depression. And, it 
is now clear, as reviewed above, that the non-interferon, oral DAA medications are highly 
effective and well tolerated in adults.  There is only very limited data on DAA treatment in 
children. In the first ‘all oral’ pediatric trial reported, the use of fixed-dose combination 
sofosbuvir/ledipasvir in children 12-17 years-old infected with HCV genotype 1 demonstrated 
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satisfactory pharmacokinetic and tolerability profiles and high rates of SVR12 (98%) (26). 
Similar excellent results were recently reported in abstract form for the combination of 
sofosbuvir–ribavirin in adolescents with HCV genotype 2 and 3 infection with SVR of 100% and 
97%, respectively (27).   
Treatment of Children with DAAs: is Delay of Therapy Justified? 
 Our limited ability to risk-stratify patients with minimal HCV disease coupled with a 
poor understanding of the dynamics progression of chronic HCV infection makes it important to 
recognize the extraordinary efficacy of new, oral DAA therapy for ALL patients with HCV.  In 
fact, the DAA therapeutic revolution raises the prospect of genuinely eradicating HCV infection.  
In order to achieve this goal; however, DAA cost analyses will be essential in developed and 
resource-limited countries, in addition to creation of effective HCV screening programs with 
effective linkage to quality patient care facilities.   
 In terms of cost-effectiveness, patient age is an important determining factor (28).  
Treatment of younger individuals i.e., children, is more cost-saving per quality-adjusted-life year 
than treating adults, and pediatric weight-based DAA dosing translates into a need for less 
medication with subsequent reduced drug costs.   Also, the projected long-term cost of medical 
follow-up is probably less in children than in adults (29).  Furthermore, early-in-life eradication 
of HCV may be important before high-risk adolescent behaviors such as injection-drug use, 
obtaining tattoos in an unregulated setting and unprotected sexual activity contribute to the 
spread of infection.  The commitment of motivated parents to adhere to a prescribed antiviral 
regimen, enhances pediatric compliance that is critically important to achieve therapeutic success 
(30). Moreover, co-morbidities such HIV co-infection, renal impairment, illegal drug and alcohol 
misuse, and decompensated cirrhosis that may portend unfavourable treatment outcomes are 
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uncommon in children (29). Curing HCV infection in females before they achieve childbearing 
age might be the best approach to preventing future vertical transmission.  Thus, HCV screening 
of high-risk mothers and their infants should be performed. 
 Have children been left behind in the HCV treatment revolution?  As noted, partial 
results of only two DAA pediatric trials  have been reported to date 26, 27) while others are 
ongoing.  In addition, several developmental plans to support authorization of combination DAA 
regimens for children have been submitted by pharmaceutical companies to the European 
Medicines Agency (EMA) and FDA, but the current timelines for completion of approved plans 
are in the distant future.  For example, the estimated date of completion of a sofosbuvir with 
ribavirin trial for children infected with HCV genotype 2 and 3 is April 2018 (clinicaltrial.gov 
identifier NCT02175758).  For children with HCV genotype 1 and 4 infection, the estimated date 
of completion of a sofosbuvir and ledipasvir +/- ribavirin trial (identifier NCT02249182) and a 
paritaprevir boosted with ritonavir/ombitasvir+/- dasabuvir (an NS5B inhibitor) +/-ribavirin trial 
(identifier NCT02486406) are May 2018 and September 2019, respectively.  The long delay is a 
direct consequence of multiple barriers which impede rapid drug registration and pediatric-
regulatory requirements.  In many high-HCV prevalent nations, trial recruitment is also hindered 
by regulations that require either drug approval by EMA and/or FDA.  To hasten pediatric access 
to new DAA therapies, in December 2014 the EMA approved a strategic approach for the 
registration of children’s DAA regimens (31).  Because of the high efficacy and excellent DAA 
safety profile in adults, new treatment regimens can now be approved for children in Europe on 
the basis of phase 1 and 2 trial studies of only 30 to 40 participants.  Also, in May 2016, the FDA 
recommended that pharmaceutical companies focus on development of DAAs for children, 
especially for the best studied regimens based on collaborative adult data (32).  The FDA also 
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advocated for earlier development of pediatric DAA drugs; and, more importantly, for the 
inclusion of younger adolescents in adult phase 3 trials (40).  The above will hopefully accelerate 
registration of DAA regimens for all children. 
 The cure of HCV infection is possible for almost all individuals treated with interferon-
free, oral DAA combination regimens.  Global elimination of hepatitis C virus is presently 
hampered by the above noted barriers, especially poor screening and identification of infected 
people, and the high price tag of expensive, but very efficacious and safe DAA drugs.  We 
believe that children should be an integral component of the public health approach required for 
success in realizing global eradication of HCV infection.  The close interplay between pediatric 
researchers, appropriate healthcare regulators and pharmaceutical industry leaders is essential in 
order to accelerate the opportunity for children to receive curative oral DAA therapy to combat 
chronic hepatitis C virus infection. 
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Table 1. New direct acting antivirals approved or in the pipeline for treating HCV infection. 
Class Suffix Approved In the pipeline  
NS3/4A protease inhibitors 
 
- previr Boceprevir (taken off the market) 
Telaprevir (taken off the market) 
 
Simeprevir 
Asunaprevir  
Paritaprevir (boosted with ritonavir) 
Grazoprevir 
Voxilaprevir 
Glecaprevir 
Sovaprevir 
NS5A inhibitors - asvir Daclatasvir 
Ledipasvir 
Ombitasvir 
Elbasvir 
Velpatasvir 
Odalasvir 
Pibrentasvir 
Ruzasvir 
Samatasvir 
NS5B polymerase inhibitors 
 
- buvir Sofosbuvir 
Dasabuvir 
Beclabuvir  
MK-3682 
ACH-3422 
AL-335 
GS-9669 
MK-8876 
 
